Web-Based Survey of Fertility Issues in Young Women With Breast Cancer

Partridge, Ann H.; Gelber, Shari; Peppercorn, Jeffrey; Sampson, E.; Knudsen, Katherine; Laufer, Marc R.; Rosenberg, R.; Przypyszny, M.; Rein, Alison; Winer, Eric P.

doi:10.1200/jco.2004.01.159

Cited by 690 publications

(553 citation statements)

References 45 publications

Supporting

Mentioning

489

Contrasting

Unclassified

Order By: Relevance

“…Early detection and improvements in screening have increased the number of premenopausal women diagnosed with breast cancer, while advances in treatment options have contributed to declining breast cancer mortality rates [1,2]. With increasing numbers of breast cancer survivors, quality of life issues such as the delayed effects of cancer treatments and fertility preservation have gained prominence [3][4][5][6]. Embryo and mature oocyte cryopreservation are currently the most established techniques for fertility preservation [7,8].…”

Section: Introductionmentioning

confidence: 99%

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Reddy

Turan

Bedoschi

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation. Methods One hundred twenty-nine women aged≤45 years, diagnosed with stage≤3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation was achieved utilizing letrozole and gonadotropins. Oocyte maturation was triggered with GnRHa or hCG. Baseline AMH levels, number of oocytes, maturation and fertilization rates, number of embryos, and the incidence of OHSS was recorded. Results The serum AMH levels were similar between GnRHa and hCG groups (2.7±1.9 vs. 2.1±1.8; p=0.327). There was one case of mild or moderate OHSS in the GnRHa group compared to 12 in the hCG group (2.1 % vs. 14.4 %, p=0.032). The maturation and fertilization rates, and the number of cryopreserved embryos were significantly higher in the GnRHa group.Conclusions GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancer patients undergoing fertility preservation.

show abstract

Section: Introductionmentioning

confidence: 99%

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Reddy

Turan

Bedoschi

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…The most commonly used adjuvant chemotherapy regimens use agents with a well-recognized negative impact on fertility [4,13]. Studies have shown that reproductive concerns play an important role for young women diagnosed with breast cancer [14,15]. In a study using a Web-based survey, 29% of women stated that infertility concerns influenced their treatment decisions [15].…”

Section: Introductionmentioning

confidence: 99%

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy

2006

View full text Add to dashboard Cite

show abstract

“…Infertility or concerns about (in)fertility due to cancer treatment have a negative influence on quality of life (Partridge et al, 2004;Wenzel, DeAlba, et al, 2005). Therefore, interest in possibilities for fertility preservation (FP) has increased.…”

Section: Introductionmentioning

confidence: 99%

Feasibility and effects of a decision aid about fertility preservation

et al. 2016

View full text Add to dashboard Cite

This paper reports on the feasibility and preliminary effects of a decision aid (DA) about female fertility preservation (FP). We conducted a pilot multicentre randomized controlled trial of women with breast cancer aged 18-40 who were randomized to brochures or the DA. Over 18 months, 62 women were eligible, of which 42 were invited by their healthcare provider (74%) to participate in the study. A total of 36 women signed up for participation and 26 (72%) were randomized to brochures (n ¼ 13) or the DA (n ¼ 13). In both groups, many women (87%) read the brochures and eight women used all available brochures. In the intervention group, 7/13 women logged in to the DA. Women who received brochures had slightly less decisional conflict, whereas knowledge improved in both groups. Our results indicate that both brochures about FP and a detailed DA have beneficial effects with regard to knowledge, but the DA seemed to introduce slightly more decisional conflict (DC) than the brochures. Although we encountered challenges with recruitment, our design and measurements seem feasible and the effects of the information materials seem promising, hence justifying conducting a larger study. ARTICLE HISTORY

show abstract

Web-Based Survey of Fertility Issues in Young Women With Breast Cancer

Abstract: Fertility after treatment is a major concern for young women with breast cancer. There is a need to communicate with and educate young patients regarding fertility issues at diagnosis and a need for future research directed at preserving fertility for young breast cancer survivors.

Cited by 690 publications

References 45 publications

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy

Feasibility and effects of a decision aid about fertility preservation

Contact Info

Product

Resources

About